Focus on Architectural Design Process through Learning Styles

Cataloged from PDF version of article.Learning as an interactive process is an important issue in architectural design education. This study aims to focus on architectural design process through learning styles that are 'accommodating', 'diverging', 'assimilating' and 'converging' as stated in the Experiential Learning Theory of Kolb. A research was conducted to evaluate the effects of learning style preferences on the performance of design students in a design process. It was found that there were statistically significant differences between the performance scores of students having diverse learning styles at various stages of design process. Also, it was found that performance scores of all students having different learning styles had increased at the end of the design process where the progress of assimilating learners were the highest and accommodating learners the lowest

Universal Product Design Involving Elderly Users: A Participatory Design Model

Cataloged from PDF version of article.Recent studies have shown that people prefer to age in their familiar environments, thus guiding designers to provide a safe and functionally appropriate environment for ageing people, regardless of their physical conditions or limitations. Therefore, a participatory design model is proposed where human beings can improve their quality of life by promoting independence, as well as safety, useability and attractiveness of the residence. Brainstorming, scenario building, unstructured interviews, sketching and videotaping are used as techniques in the participatory design sessions. Quality deployment matrices are employed to find the relationships between the elderly user's requirements and design specifications. A case study was devised to apply and test the conceptual model phase of the proposed model. (C) 2004 Elsevier Ltd. All rights reserved

Universal product design involving elderly users: A participatory design model

Recent studies have shown that people prefer to age in their familiar environments, thus guiding designers to provide a safe and functionally appropriate environment for ageing people, regardless of their physical conditions or limitations. Therefore, a participatory design model is proposed where human beings can improve their quality of life by promoting independence, as well as safety, useability and attractiveness of the residence. Brainstorming, scenario building, unstructured interviews, sketching and videotaping are used as techniques in the participatory design sessions. Quality deployment matrices are employed to find the relationships between the elderly user's requirements and design specifications. A case study was devised to apply and test the conceptual model phase of the proposed model. © 2004 Elsevier Ltd. All rights reserved

Acute brucella melitensis M16 infection model in mice treated with tumor necrosis factor-alpha inhibitors

Introduction: There is limited data in the literature about brucellosis related to an intracellular pathogen and anti-tumor necrosis factor alpha (anti-TNFα) medication. The aim of this study was to evaluate acute Brucella infections in mice receiving anti-TNFα drug treatment. Methodology: Anti-TNFα drugs were injected in mice on the first and fifth days of the study, after which the mice were infected with B. melitensis M16 strain. Mice were sacrificed on the fourteenth day after infection. Bacterial loads in the liver and spleen were defined, and histopathological changes were evaluated. Results: Neither the liver nor the spleen showed an increased bacterial load in all anti-TNFα drug groups when compared to a non-treated, infected group. The most significant histopathological findings were neutrophil infiltrations in the red pulp of the spleen and apoptotic cells with hepatocellular pleomorphism in the liver. There was no significant difference among the groups in terms of previously reported histopathological findings, such as extramedullary hematopoiesis and granuloma formation. Conclusions: There were no differences in hepatic and splenic bacterial load and granuloma formation, which indicate worsening of the acute Brucella infection in mice; in other words, anti-TNFα treatment did not exacerbate the acute Brucella spp. infection in mice. © 2015 Kutlu et al

Involving the elderly in the design process

Based on the concept of 'aging in place', a prescriptive model is proposed, aiming at the creation of a usable, safe and attractive built environment where the elderly residents are actively involved in the design process through collaboration sessions. Quality Function Deployment (QFD) has been adapted to develop an evaluation and translation method for the collected data of the elderly end-users

Retrospective long-term results and prognostic factors of treatment for colorectal cancer

To evaluate retrospectively 5-10 year overall survival rate in patients with colorectal cancer treated with or without adjuvant therapy for early stage and analyze the impact of some prognostic factors on clinical outcome we retrospectively reviewed 56 patients treated with only surgery, postoperative or preoperative 5-fluorouracil-based chemotherapy and radiotherapy. The following prognostic factors were considered at univariate analyses: age, sex, tumor location, pathological, tumoural and nodal stage, surgical procedure, pathological specimen margins and adjuvant treatment if applied. The 5 and 10 year actuarial rates for overall survival (OS) were 66% and relapse free survival (RFS) rates were 83% and 58% respectively for all patients. Five years survival was 100%, 73% and 44% respectively for stages I, II and III (p< 0.01). Five years survival for N0, NI and NII disease were 81.3%, 75% and 0% respectively (p< 0.01). Better prognosis was observed for colon cancer compared to rectal and rectosigmoid tumors: 5 years survival rates 90%, 70% and 40% respectively (p< 0.01). Univariate analysis showed that nodal disease, location of tumor in a subsite of colon, pathological stage and surgical procedure had an impact on survival. Our retrospective study showed a good 5-10 year overall survival. Factors as individual pN2, tumor location and advanced pathological stage negatively influenced survival rates. In our opinion to achive better results especially in N2 cancer and rectal and rectosigmoid tumors, especially use of appropriate chemoradiation protocols and new high art radiation technology must be considered in clinical studies in advance

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

BACKGROUND Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials that showed efficacy and manageable toxic effects. METHODS In this multi-institutional phase 3 trial, we randomly assigned adults with heavily pretreated B-cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standardof- care chemotherapy. The primary end point was overall survival. RESULTS Of the 405 patients who were randomly assigned to receive blinatumomab (271 patients) or chemotherapy (134 patients), 376 patients received at least one dose. Overall survival was significantly longer in the blinatumomab group than in the chemotherapy group. The median overall survival was 7.7 months in the blinatumomab group and 4.0 months in the chemotherapy group (hazard ratio for death with blinatumomab vs. chemotherapy, 0.71; 95% confidence interval [CI], 0.55 to 0.93; P = 0.01). Remission rates within 12 weeks after treatment initiation were significantly higher in the blinatumomab group than in the chemotherapy group, both with respect to complete remission with full hematologic recovery (34% vs. 16%, P<0.001) and with respect to complete remission with full, partial, or incomplete hematologic recovery (44% vs. 25%, P<0.001). Treatment with blinatumomab resulted in a higher rate of event-free survival than that with chemotherapy (6-month estimates, 31% vs. 12%; hazard ratio for an event of relapse after achieving a complete remission with full, partial, or incomplete hematologic recovery, or death, 0.55; 95% CI, 0.43 to 0.71; P<0.001), as well as a longer median duration of remission (7.3 vs. 4.6 months). A total of 24% of the patients in each treatment group underwent allogeneic stem-cell transplantation. Adverse events of grade 3 or higher were reported in 87% of the patients in the blinatumomab group and in 92% of the patients in the chemotherapy group. CONCLUSIONS Treatment with blinatumomab resulted in significantly longer overall survival than chemotherapy among adult patients with relapsed or refractory B-cell precursor ALL. (Funded by Amgen; TOWER ClinicalTrials.gov number, NCT02013167.

Prostatic sarcoma after treatment of rectal cancer

<p>Abstract</p> <p>Background</p> <p>The relationship between radiation exposure for treatment of cancer and occurrence of a second primary cancer at the irradiated site is well known. This phenomenon is however rare in prostate.</p> <p>Case presentation</p> <p>A 75-year-old farmer was treated for rectal cancer with preoperative 45 Gy of radiotherapy and abdominoperineal resection. Four years later he developed symptoms of bladder outlet obstruction and acute urinary retention. He underwent a transurethral resection of the prostate. Histological examination of the removed prostate tissue and immunohistochemistry revealed it to be a poorly differentiated sarcoma.</p> <p>Conclusion</p> <p>We believe this to be the first reported case of radiation-induced sarcoma following radiotherapy treatment for rectal cancer. Since radiotherapy plays a pivotal role in the contemporary treatment of rectal adenocarcinoma, it is relevant to be aware of the potential long-term carcinogenic complications of radiotherapy of the pelvis.</p